Inactive Instrument

Sio Gene Therapies Inc.

Equities

SIOX

US8293991043

Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021

February 11, 2022 at 07:01 am EST

Sio Gene Therapies Inc. reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported net loss was USD 25.46 million compared to USD 10.52 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.2 a year ago.
For the nine months, net loss was USD 58.56 million compared to USD 29.09 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 0.61 a year ago.

Latest news about Sio Gene Therapies Inc.

Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index	23-03-27	CI
Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index	23-03-22	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours	22-12-14	MT
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
Sio Gene Therapies Inc.(NasdaqGS:SIOX) dropped from S&P Global BMI Index	22-06-20	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-14	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-06-14	CI
Top Premarket Decliners	22-04-28	MT
HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	22-04-28	MT
Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	22-04-28	MT
Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value	22-04-26	CI
Sio Gene Therapies Receives Nasdaq Listing Noncompliance Notice Over Minimum Closing Price	22-03-18	MT
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11	CI
Health Care Stocks Back Near Even For Tuesday Trading	22-02-01	MT
Sector Update: Health Care	22-02-01	MT
Top Midday Decliners	22-02-01	MT
Cantor Adjusts Sio Gene Therapies Price Target to $3 From $8, Maintains Overweight Rating	22-02-01	MT
HC Wainwright Adjusts Price Target on Sio Gene Therapies to $7 From $10, Reiterates Buy Rating	22-02-01	MT
SVB Leerink Downgrades Sio Gene Therapies to Market Perform From Outperform, Adjusts Price Target to $1 From $6	22-02-01	MT
Sio Gene Therapies Ends Gene Therapy Program for Parkinson's Disease, Names New CEO	22-02-01	MT
Sio Gene Therapies Terminates Oxford Biomedica's Parkinson's Disease Gene Therapy Program	22-02-01	MT
Sio Gene Therapies Inc. Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis	22-01-31	CI
Sio Gene Therapies Inc. Announces Executive Changes	22-01-31	CI

Chart Sio Gene Therapies Inc.

Duration

Period

More charts

Company Profile

Sio Gene Therapies Inc. was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The Company has not generated any revenue.

Sector

More about the company